Atropisomerism transforming anti‐cancer drug discovery

Abstract

Atropisomerism is a stereochemical phenomenon that describes how groups are arranged in space as a result of their impeded rotation around a single bond. It is one of the frequently underappreciated conformational kinds of chirality. A significant role for atropisomers in drug discovery and development has been established via substantial study on the characteristics of molecules exhibiting this form of chirality. According to studies on the target selectivity of anti‐cancer drugs, it was identified that atropisomers of specific compounds could be examined to modulate the selectivity of promiscuous inhibitors, which are a key target in cancer therapy. Conversely, it was discovered that these deliberate rigidifications of possible molecules along an axis of chirality gave an abundant possibility of acquiring more tailored anti‐cancer action. Atropisomerism plays a significant role in altering pharmacodynamic and pharmacokinetic properties and thereby the success of any proposed drug candidate. It is thus necessary to anticipate the impact of stereogenic centres in such compounds on cancer drug development. Hence, herein we review atropisomeric anti‐cancer moieties which have been investigated based on their target proteins, origin and isomerism. The insights offered herein would be extremely useful in anti‐cancer drug design, pave way for new avenues to development promising potent agents to combat this life‐threatening disease.

Organocatalytic Asymmetric Synthesis of Carbo- and Oxacyclic Seven-Membered Bridged Biaryls via Nucleophile-Dependent Switchable Domino Processes

“…Biaryl atropisomers have attracted attention in asymmetric synthesis as they constitute an integral skeleton of selected bioactive natural products and chiral catalysts, including chiral ligands and organocatalysts . The probability of resolution of atropoisomers could be further enhanced by introducing a bridge between two biaryl rings, thereby restricting the rotation around the C–C bond .…”